Cargando…

Oral topotecan: bioavailability and effect of food co-administration

The aims of the study were twofold: (1) to evaluate the effect of food on the relative oral bioavailability of topotecan gelatin capsules in patients with solid tumours, and (2) to determine the absolute bioavailability of oral topotecan with reference to the intravenous (i.v.) formulation. The stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herben, V M M, Rosing, H, Huinink, W W ten Bokkel, Zomeren, D M van, Batchelor, D, Doyle, E, Beusenberg, F D, Beijnen, J H, Schellens, J H M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1999
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363072/ https://www.ncbi.nlm.nih.gov/pubmed/10424739 http://dx.doi.org/10.1038/sj.bjc.6690532

Ejemplares similares

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
por: Herben, V. M., et al.
Publicado: (1997)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999)

A phase I and pharmacokinetic study of intraperitoneal topotecan
por: Hofstra, L S, et al.
Publicado: (2001)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
por: Kuin, A, et al.
Publicado: (1999)

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
por: Schoemaker, N E, et al.
Publicado: (2002)

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
por: Helgason, H H, et al.
Publicado: (2006)

Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer
por: Gelderblom, H, et al.
Publicado: (2001)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
por: Tellingen, O van, et al.
Publicado: (1999)

Protein versus DNA as a marker for peripheral blood mononuclear cell counting
por: Jansen, Robert S., et al.
Publicado: (2009)

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010)

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
por: Ma, J., et al.
Publicado: (1998)

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer
por: Gore, M, et al.
Publicado: (2001)

Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen
por: Jager, N. G. L., et al.
Publicado: (2012)

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment
por: van Andel, Lotte, et al.
Publicado: (2018)

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
por: Schoemaker, N E, et al.
Publicado: (2004)

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar()
por: Sawicki, Emilia, et al.
Publicado: (2016)

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
por: Dercksen, M. W., et al.
Publicado: (1993)

Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents
por: Lee, Jaeok, et al.
Publicado: (2021)

No relation between docetaxel administration route and high‐grade diarrhea incidence
por: Hendrikx, Jeroen J. M. A., et al.
Publicado: (2020)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
por: Kerklaan, B Milojkovic, et al.
Publicado: (2015)

A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
por: Arends, J J, et al.
Publicado: (2005)

Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines
por: Vanhoefer, U, et al.
Publicado: (1999)

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
por: de Wit, R., et al.
Publicado: (1995)

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
por: McLeod, H. L., et al.
Publicado: (1996)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
por: van der Noll, R., et al.
Publicado: (2015)

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Lactone Stabilized by Crosslinked Cyclodextrin Metal-Organic Frameworks to Improve Local Bioavailability of Topotecan in Lung Cancer
por: Xiong, Ting, et al.
Publicado: (2022)

Pharmacokinetics and Excretion of (14)C-Bendamustine in Patients with Relapsed or Refractory Malignancy
por: Dubbelman, Anne-Charlotte, et al.
Publicado: (2013)

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
por: de Wit, R., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_hp0dr95arcatv8emkneghhap13